What does Axepharma do?

Axepharma is a pharmacy in Beernem. Private Limited, started on 12 December 2019, 1 establishment.

What is the address of Axepharma?

The registered office of Axepharma is located at Beverhoutsveldstraat 64, 8730 Beernem.

Is Axepharma still active?

Yes. According to the CBE (30 October 2026) Axepharma is active, legal situation “Normale toestand”, started on 12 December 2019.

Is Axepharma registered on Peppol?

Yes, Axepharma is registered on the Peppol network with ID 0208:0739549477.

What is the enterprise number of Axepharma?

The enterprise number of Axepharma is BE0739549477.

When was Axepharma founded?

Axepharma was founded on 12 December 2019.

Who are the directors of Axepharma?

According to the 2025 annual accounts, the directors of Axepharma are: Koen Thenaers, Wendy Vandenbussche.

Is Axepharma a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 12 December 2019; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did Axepharma make in 2025?

Axepharma posted a profit after taxes of € 65,629 in financial year 2025.

What is the revenue of Axepharma?

As a small company, Axepharma is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 151,840.

How much does an employee at Axepharma earn?

The average wage cost per full-time employee at Axepharma was € 44,800 in 2025: staff costs of € 49,250 for 1.1 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does Axepharma have?

According to the 2025 annual accounts, Axepharma has 1.1 full-time equivalents (FTE).

Axepharma (Private Limited) - Beernem - BE0739549477

Dossier Axepharma, printed on 30 October 2026 from databakkes.be/en/0739549477/axepharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

Axepharma from Beernem, company number BE0739549477, closed financial year 2025 with a result of € 65,629 after tax. For that financial year Axepharma recorded a gross margin of € 151,840 and equity of € 310,130. Compared with financial year 2024, the result moved from € 58,188 to € 65,629. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on May 26, 2026.

What it is worth Growing

€ 310,130

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 65,629

▲ 13% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 177,525

▲ 79% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 63,000 paid out

96 % of the profit went to the shareholders, the rest stayed in the company.

People and assets in 2025

Full-time equivalents

1.1

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 49,250

▼ 6% vs 2024

€ 44,800 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 4,886

▲ € 3,696 vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 41,212

▼ 8% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Wages and social charges

€ 5,801

▼ 30% vs 2024

Wages, holiday pay and social contributions still to pay. No outstanding taxes.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 152,867 Gross margin 2022: € 152,867 First fiscal year in the series	€ 129,552 Gross margin 2023: € 129,552 ▼ 15% vs 2022 (€ 152,867) Unfavourable step	€ 145,052 Gross margin 2024: € 145,052 ▲ 12% vs 2023 (€ 129,552) Favourable step	€ 151,840 Gross margin 2025: € 151,840 ▲ 5% vs 2024 (€ 145,052) Favourable step	▲ 5%
Profit after taxes	€ 69,445 Profit after taxes 2022: € 69,445 First fiscal year in the series	€ 49,132 Profit after taxes 2023: € 49,132 ▼ 29% vs 2022 (€ 69,445) Unfavourable step	€ 58,188 Profit after taxes 2024: € 58,188 ▲ 18% vs 2023 (€ 49,132) Favourable step	€ 65,629 Profit after taxes 2025: € 65,629 ▲ 13% vs 2024 (€ 58,188) Favourable step	▲ 13%
Equity	€ 204,846 Equity 2022: € 204,846 First fiscal year in the series	€ 253,978 Equity 2023: € 253,978 ▲ 24% vs 2022 (€ 204,846) Favourable step	€ 309,856 Equity 2024: € 309,856 ▲ 22% vs 2023 (€ 253,978) Favourable step	€ 310,130 Equity 2025: € 310,130 Unchanged (€ 309,856) Favourable step
Total debts	€ 84,391 Total debts 2022: € 84,391 First fiscal year in the series	€ 76,531 Total debts 2023: € 76,531 ▼ 9% vs 2022 (€ 84,391) Favourable step	€ 78,910 Total debts 2024: € 78,910 ▲ 3% vs 2023 (€ 76,531) Unfavourable step	€ 131,999 Total debts 2025: € 131,999 ▲ 67% vs 2024 (€ 78,910) Unfavourable step	▲ 67%
Cash	€ 99,099 Cash 2022: € 99,099 First fiscal year in the series	€ 49,509 Cash 2023: € 49,509 ▼ 50% vs 2022 (€ 99,099) Unfavourable step	€ 98,978 Cash 2024: € 98,978 ▲ 100% vs 2023 (€ 49,509) Favourable step	€ 177,525 Cash 2025: € 177,525 ▲ 79% vs 2024 (€ 98,978) Favourable step	▲ 79%
Retained profit	€ 194,846 Retained profit 2022: € 194,846 First fiscal year in the series	€ 243,978 Retained profit 2023: € 243,978 ▲ 25% vs 2022 (€ 194,846) Favourable step	€ 299,856 Retained profit 2024: € 299,856 ▲ 23% vs 2023 (€ 243,978) Favourable step	€ 300,130 Retained profit 2025: € 300,130 Unchanged (€ 299,856) Favourable step
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 0 Dividend 2023: € 0 Unchanged (€ 0) Unchanged	€ 0 Dividend 2024: € 0 Unchanged (€ 0) Unchanged	€ 63,000 Dividend 2025: € 63,000 Unchanged (€ 0) Unchanged
Bank debt	€ 40,742 Bank debt 2022: € 40,742 First fiscal year in the series	€ 21,284 Bank debt 2023: € 21,284 ▼ 48% vs 2022 (€ 40,742) Favourable step	€ 1,645 Bank debt 2024: € 1,645 ▼ 92% vs 2023 (€ 21,284) Favourable step	€ 0 Bank debt 2025: € 0 ▼ 100% vs 2024 (€ 1,645) Favourable step	▼ 100%
Balance sheet total	€ 289,236 Balance sheet total 2022: € 289,236 First fiscal year in the series	€ 330,509 Balance sheet total 2023: € 330,509 ▲ 14% vs 2022 (€ 289,236) Unchanged	€ 388,765 Balance sheet total 2024: € 388,765 ▲ 18% vs 2023 (€ 330,509) Unchanged	€ 442,129 Balance sheet total 2025: € 442,129 ▲ 14% vs 2024 (€ 388,765) Unchanged	▲ 14%
Employees (FTE)	-	-	-	1.1 Employees (FTE) 2025: 1.1 First fiscal year in the series

Key figures of Axepharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Axepharma?

What happened at Axepharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

May 26, 2026 New annual accounts for financial year 2025: profit of € 65,629 (▲ 13% vs 2024). Source: NBB ↗
2020 Wendy Vandenbussche became a director. NBB
Dec 12, 2019 New establishment in Brugge. KBO
Dec 12, 2019 Start of the company according to the CBE. KBO
2019 Koen Thenaers became a director. NBB

In short

From € 69,445 profit in 2022 to € 65,629 profit in 2025.

Paid € 86,187 in corporate taxes since 2022.

Best year ever: 2022, with € 69,445 profit.

On average € 138,000 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

Koen Thenaers Wendy Vandenbussche

PLUS-VALUES

Axepharma

Behind Axepharma are Koen Thenaers and Wendy Vandenbussche. The same people are also behind PLUS-VALUES.

Directors

According to the 2025 annual accounts

Koen Thenaers

Director

Also active at: PLUS-VALUES

since 2019

Wendy Vandenbussche

Director

Also active at: PLUS-VALUES

since 2020

Establishments

Establishment units

Physical locations of this company

Registered office

Beverhoutsveldstraat 64

8730 Beernem

2.296.535.970

Smedenstraat 73

8000 Brugge

Active since 12 December 2019

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

PLUS-VALUES same network

€ 3,676 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0739.549.477
VAT number: BE 0739.549.477
Registered office: Beverhoutsveldstraat 64, 8730 Beernem
Names & denominations: Axepharma
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 12 December 2019
Peppol: Active · Active since 8 Nov 2024
Contact: [email protected]
Activities · NACE: Detailhandel in farmaceutische producten

View on CBE Public ↗ Annual accounts (NBB) ↗